RecruitingPhase 1NCT06136195
Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
Sponsor
Yale University
Enrollment
63 participants
Start Date
Jul 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.
Eligibility
Min Age: 21 YearsMax Age: 50 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Mavoglurant for people with alcohol consumption, alcohol use disorder (aud), and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 21 Years to 50 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMavoglurant
The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06136195
Related Trials
Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms
NCT064840751 location
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
NCT075595001 location
Drinking, Acetate, and Stress
NCT065844482 locations
Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974
NCT074888191 location
Optimizing Smart Technology for Addiction Recovery
NCT075735401 location